Birmingham-based molecular diagnostics company BioGX has purchased a building on Valleydale Road in Shelby County that will house its corporate headquarters and expanded research and development and manufacturing capabilities. The company will progress from its current location at the Innovation Depot and move to the new facility in several phases in 2021, making an investment of around $5 million.
The BioGX multiplex COVID-19, Flu A, Flu B and RSV test is intended for the qualitative detection of RNA specific to SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus A/B that may be present in Pharyngeal and Nasopharyngeal swab collections in transport media and saline, obtained from individuals at risk of respiratory viral infections.
The American MedTech firm BioGX is supplying coronavirus test kits worldwide from its global office and lab in Amsterdam Science Park. “Everyone is coming together to help, they recognise the importance of mass testing,” CEO Dr Shazi Iqbal explains to I amsterdam how the company is working to fight the global coronavirus outbreak.
The past few months has shown that a team’s rapid response to expediting an assay globally, dedicated to the detection of SARS-CoV-2, is possible. BioGX, in a long-term partnership with Becton, Dickinson and Company, has submitted a test to the FDA for emergency use authorisation (EUA) in the US, in parallel to CE-IVD approval. In these challenging times, laboratories around the world have an urgent need for an easy-to-use, reliable test to detect SARS-CoV-2 to determine if patients have contracted COVID-19. Authorisation to use these tests worldwide would increase access to highly reliable results.
Montgomery, AL, March 8, 2017 – BioGX was honored as one of eight (8) companies selected as a 2017 Governor’s Trade Excellence Awards recipient during a ceremony at the state Capitol in Montgomery, AL. Read more
The BioGX EcLiSa test is used for testing fresh produce for contaminating bacteria like E. coli, Salmonella, and Listeria. Our work with the University of North Carolina at Chapel Hill has recently been featured in a spotlight article and video titled, “Science for safer food”. CLICK HERE to link to the article.
ASM/Microbe 2016: ARUP presents a pivotal poster on assays for Molecular testing of gastrointestinal (GI) pathogens causing acute diarrhea using of BioGX’s Sample Ready technology. Read more
ASM/Microbe 2016: Tampa General presents excellent analytical data on BioGX’s Sample Ready multiplex Flu A, Flu B and RSV on a BD MAXTM open channel assay platform. Read more
ASM/Microbe 2016: ARUP presents a unique study on the detection of enteropathogenic Microsporidia with a multiplex real-time using of BioGX’s Sample Ready assay platform. Read more
BioGX now holds a Certificate of Registration for Quality Management System (QMS)- ISO 13485;2003 (Certificate No FM 642714) and now operates a QMS which complies with the requirements of ISO 13485;2003 for “the design, development, manufacture and distribution of in-vitro diagnostics and contract specified reagents for molecular diagnostics.